Eli Lilly’s Weight-Loss Pill Wins Backing in Europe
- On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Eli Lilly's weight-loss pill Foundayo for obesity and type 2 diabetes.
- The Food and Drug Administration cleared the drug in the U.S. in April, generating $98 million in revenue during the April-to-June period after its debut.
- In late-stage testing, patients on the top dose lost roughly 11% of their body weight over 72 weeks, compared to about 2% for placebo; unlike Novo Nordisk's Wegovy, Foundayo requires no specific food or water intake rules.
- Lilly has stepped up promotion, featuring lifestyle entrepreneur Martha Stewart in advertisements, after launching the drug in Britain on Aug. 24 and in the United Arab Emirates.
- The recommendation moves to the European Commission for a final ruling expected in roughly two months, as Lilly seeks approval in roughly 40 additional markets globally.
24 Articles
24 Articles
informacion.es
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for orforglipron, a commercial name 'Foundayo', Lilly's daily oral weight loss drug that can be taken at any time of the day and without restrictions on water or food. Your marketing authorisation from the European Commission is expected in the coming months, reports the medical company.
Eli Lilly's weight-loss pill wins EU drug regulator's backing
The European Medicines Agency's committee on Friday recommended approval of Eli Lilly's weight-loss pill Foundayo, the second oral obesity drug to win the agency's backing after Novo Nordisk's Wegovy pill.The recommendation will now be reviewed by the European Commission before it gives the final nod to launch the drug in the region.Both Novo and Lilly are racing to broaden access to their oral drugs, as they aim to secure a larger share of …
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has given the green light to orforglipron, an oral tablet that can be taken at any time of the day without the need for previous or subsequent fasting.
The European Medicines Agency (EMA) has recommended the marketing authorisation of Eli Lilly's anti-obesity pill Foundayo, the second oral weight loss drug to receive the authority's backing, after Novo Nordisk's Wegovy tablet was given the green light in the European Union in July.
In clinical trials, Eli Lilly's orforlipron offered weight loss of up to 10%. The EMA recommended its approval against obesity and type 2 diabetes. The post Green light in Europe for a second anti-obesity pill appeared first on in.gr.
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
